<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02114385</url>
  </required_header>
  <id_info>
    <org_study_id>V503-020</org_study_id>
    <secondary_id>2013-003399-10</secondary_id>
    <secondary_id>GDS07C</secondary_id>
    <nct_id>NCT02114385</nct_id>
  </id_info>
  <brief_title>A Study to Compare Immune Response of V503 to Gardasil in 16- to 26-year-old Men (V503-020)</brief_title>
  <official_title>A Randomized, Double-Blinded, Controlled With GARDASIL (Human Papillomavirus Vaccine [HPV] [Types 6, 11, 16, 18] (Recombinant, Adsorbed)), Phase 3 Clinical Trial to Study the Immunogenicity and Tolerability of V503 (9-Valent Human Papillomavirus L1 Virus-Like Particle [VLP] Vaccine) in 16- to 26-year-old Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective

      To demonstrate that administration of V503 induces non-inferior Geometric Mean Titres (GMTs)
      for serum anti-HPV 6, 11, 16, and 18, compared to GARDASIL in 16- to 26-year-old men
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Secondary objectives

        -  To evaluate the tolerability of V503 in 16- to 26-year-old men.

        -  To summarise humoral immune responses, including anti-HPV 6, 11, 16, 18, 31, 33, 45, 52,
           58 GMTs and seroconversion rates at 4 weeks post-dose 3, in 16- to 26-year-old men who
           received V503 or GARDASIL
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 24, 2014</start_date>
  <completion_date type="Actual">April 22, 2015</completion_date>
  <primary_completion_date type="Actual">April 22, 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMTs) to HPV Types 6/11/16/18</measure>
    <time_frame>4 weeks postdose 3 (Month 7)</time_frame>
    <description>Serum antibodies to HPV types 6, 11, 16, and 18 were measured with a Competitive Luminex Immunoassay. Titers are reported in milli Merck Units/mL.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>GMTs to HPV Types 31/33/45/52/58</measure>
    <time_frame>4 weeks postdose 3 (Month 7)</time_frame>
    <description>Serum antibodies to HPV types 31, 33, 45, 52, and 58 were measured with a Competitive Luminex Immunoassay. Titers are reported in milli Merck Units/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Are Seropositive for HPV Types 6/11/16/18/31/33/45/52/58</measure>
    <time_frame>4 weeks postdose 3 (Month 7)</time_frame>
    <description>Serum antibodies to HPV types were measured with a Competitive Luminex Immunoassay. The serostatus cutoffs (milli Merck U/mL) for HPV types were as follows: HPV Type 6: ≥30; HPV Type 11: ≥16; HPV Type 16: ≥20; HPV Type 18: ≥24; HPV Type 31: ≥10; HPV Type 33: ≥8; HPV Type 45: ≥8; HPV Type 52: ≥8; HPV Type 58: ≥8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With One or More Adverse Events</measure>
    <time_frame>Up to 15 days after any vaccination</time_frame>
    <description>The percentage of participants with one or more adverse events was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Study Discontinuation Due to an Adverse Event</measure>
    <time_frame>Up to Month 7</time_frame>
    <description>The percentage of participants discontinued from the study due to an adverse event was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With One or More Injection-site Adverse Reactions</measure>
    <time_frame>Up to 5 days after any vaccination</time_frame>
    <description>The percentage of participants with one or more injection-site adverse reactions (solicited or unsolicited) was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Maximum Temperature ≥37.8 °C</measure>
    <time_frame>Up to 5 days after any vaccination</time_frame>
    <description>The percentage of participants with a maximum temperature ≥37.8 °C was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With One or More Systemic Adverse Events</measure>
    <time_frame>Up to 15 days after any vaccination</time_frame>
    <description>The percentage of participants with one or more systemic adverse events was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With One or More Serious Adverse Events</measure>
    <time_frame>Up to 15 days after any vaccination</time_frame>
    <description>The percentage of participants with one or more serious adverse events was assessed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">500</enrollment>
  <condition>Papilloma Viral Infection</condition>
  <arm_group>
    <arm_group_label>V503</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>9-valent HPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GARDASIL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Quadrivalent HPV [Types 6, 11, 16, and 18] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V503</intervention_name>
    <description>9-valent HPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine, 0.5-mL intramuscular injection</description>
    <arm_group_label>V503</arm_group_label>
    <other_name>9vHPV vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GARDASIL</intervention_name>
    <description>Quadrivalent HPV [Types 6, 11, 16, and 18] L1 virus-like particle vaccine, 0.5-mL intramuscular injection</description>
    <arm_group_label>GARDASIL</arm_group_label>
    <other_name>qHPV vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is a man, between the ages of 16 years and 0 days and 26 years and 364 days on
             the day of enrolment.

          -  Subject is a man who has had no more than 5 lifetime female sexual partners.

          -  Subject is judged to be in good physical health on the basis of medical history,
             physical examination, and laboratory results.

          -  Subject, or subject's parent or guardian, fully understand study procedures,
             alternative treatments available, the risks involved with the study, and voluntarily
             agree to participate by giving written informed consent.

        Exclusion Criteria:

          -  Subject who has had sex with a male partner.

          -  Subject has a history of HPV-related external genital lesions or HPV-related anal
             lesions

          -  Subject has a known allergy to any vaccine component, including aluminium, yeast, or
             BENZONASE

          -  Subject has a history of severe allergic reaction that required medical intervention.

          -  Subject has thrombocytopenia or any coagulation disorder that would contraindicate
             intramuscular injections.

          -  Subject is concurrently enrolled in clinical studies of investigational medicinal
             products.

          -  Subject has donated blood within 1 week prior to the Day 1 vaccination, or intends to
             donate during Day 1 through Month 7 of the study.

          -  Subject is currently immunocompromised or has been diagnosed as having a congenital or
             acquired immunodeficiency, HIV infection, lymphoma, leukemia, systemic lupus
             erythematosus, rheumatoid arthritis, juvenile rheumatoid arthritis, inflammatory bowel
             disease, or other autoimmune condition.

          -  Subject has had a splenectomy.

          -  Subject is receiving or has received in the year prior to enrolment the following
             immunosuppressive therapies: radiation therapy, cyclophosphamide, azathioprine,
             methotrexate, any chemotherapy, cyclosporin, leflunomide, TNF-α antagonists,
             monoclonal antibody therapies, intravenous gamma globulin, antilymphocyte sera, or
             other therapy known to interfere with the immune response.

          -  Subject has received any immune globulin product or blood-derived product within the 6
             months prior to the Day 1 vaccination, or plans to receive any such product during Day
             1 through Month 7 of the study.

          -  Subject has received non-replicating (inactivated) vaccines within 14 days prior to
             the Day 1 vaccination or has received replicating (live) vaccines within 21 days prior
             to the Day 1 vaccination.

          -  Subject has received a marketed HPV vaccine, or has participated in an HPV vaccine
             clinical trial and has received either active agent or placebo.

          -  Subject has had a fever within the 24-hour period prior to the Day 1 vaccination.

          -  Subject has a history or current evidence of any condition, therapy, laboratory
             abnormality or other circumstance that might confound the results of the study, or
             interfere with the subject's participation for the full duration of the study, such
             that it is not in the best interest of the subject to participate.

          -  Subject is unlikely to adhere to the study procedures, keep appointments, or is
             planning to relocate during the study.

          -  Subject is, at the time of signing informed consent, a user of recreational or illicit
             drugs or has had a recent history (within the last year) of drug abuse or dependence.
             Alcohol abusers are defined as those who drink despite recurrent social,
             interpersonal, and/or legal problems as a result of alcohol use.

          -  Subject, or subject's parent or guardian, is or has an immediate family member (spouse
             or children) who is investigational site or sponsor staff directly involved with this
             trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>26 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 1002</name>
      <address>
        <city>Ghent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 1003</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 1001</name>
      <address>
        <city>Wilrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 3001</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 4001</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 4003</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 4002</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Netherlands</country>
  </location_countries>
  <results_reference>
    <citation>Van Damme P, Meijer CJLM, Kieninger D, Schuyleman A, Thomas S, Luxembourg A, Baudin M. A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men. Vaccine. 2016 Jul 29;34(35):4205-4212. doi: 10.1016/j.vaccine.2016.06.056. Epub 2016 Jun 25.</citation>
    <PMID>27354258</PMID>
  </results_reference>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>April 8, 2014</study_first_submitted>
  <study_first_submitted_qc>April 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2014</study_first_posted>
  <results_first_submitted>August 3, 2017</results_first_submitted>
  <results_first_submitted_qc>February 20, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 1, 2018</results_first_posted>
  <last_update_submitted>February 20, 2018</last_update_submitted>
  <last_update_submitted_qc>February 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Papillomavirus Infections</mesh_term>
    <mesh_term>Papilloma</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 502 participants were screened and 500 were randomized</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>V503</title>
          <description>9-valent HPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6</description>
        </group>
        <group group_id="P2">
          <title>GARDASIL</title>
          <description>Quadrivalent HPV [Types 6, 11, 16, and 18] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="249"/>
                <participants group_id="P2" count="251"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated</title>
              <participants_list>
                <participants group_id="P1" count="249"/>
                <participants group_id="P2" count="251"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="246"/>
                <participants group_id="P2" count="243"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Randomized participants</population>
      <group_list>
        <group group_id="B1">
          <title>V503</title>
          <description>9-valent HPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6</description>
        </group>
        <group group_id="B2">
          <title>GARDASIL</title>
          <description>Quadrivalent HPV [Types 6, 11, 16, and 18] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="249"/>
            <count group_id="B2" value="251"/>
            <count group_id="B3" value="500"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.8" spread="2.7"/>
                    <measurement group_id="B2" value="21.3" spread="3.0"/>
                    <measurement group_id="B3" value="21.0" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;18 years old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=18 years old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="212"/>
                    <measurement group_id="B2" value="213"/>
                    <measurement group_id="B3" value="425"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="249"/>
                    <measurement group_id="B2" value="251"/>
                    <measurement group_id="B3" value="500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers (GMTs) to HPV Types 6/11/16/18</title>
        <description>Serum antibodies to HPV types 6, 11, 16, and 18 were measured with a Competitive Luminex Immunoassay. Titers are reported in milli Merck Units/mL.</description>
        <time_frame>4 weeks postdose 3 (Month 7)</time_frame>
        <population>All randomized participants. The number contributing to each data point is participants who received all 3 vaccinations within acceptable day ranges, had Month 7 serology for the HPV type within acceptable day ranges, were seronegative at Day 1, and had no protocol violations that interfered with evaluation of immune response.</population>
        <group_list>
          <group group_id="O1">
            <title>V503</title>
            <description>9-valent HPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6</description>
          </group>
          <group group_id="O2">
            <title>GARDASIL</title>
            <description>Quadrivalent HPV [Types 6, 11, 16, and 18] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) to HPV Types 6/11/16/18</title>
          <description>Serum antibodies to HPV types 6, 11, 16, and 18 were measured with a Competitive Luminex Immunoassay. Titers are reported in milli Merck Units/mL.</description>
          <population>All randomized participants. The number contributing to each data point is participants who received all 3 vaccinations within acceptable day ranges, had Month 7 serology for the HPV type within acceptable day ranges, were seronegative at Day 1, and had no protocol violations that interfered with evaluation of immune response.</population>
          <units>milli Merck U/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="251"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV Type 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="228"/>
                    <count group_id="O2" value="226"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="758.3" lower_limit="665.9" upper_limit="863.4"/>
                    <measurement group_id="O2" value="618.4" lower_limit="554.0" upper_limit="690.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV Type 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="228"/>
                    <count group_id="O2" value="226"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="681.7" lower_limit="608.9" upper_limit="763.4"/>
                    <measurement group_id="O2" value="769.1" lower_limit="683.5" upper_limit="865.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV Type 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="234"/>
                    <count group_id="O2" value="237"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3924.1" lower_limit="3513.8" upper_limit="4382.3"/>
                    <measurement group_id="O2" value="3787.9" lower_limit="3378.4" upper_limit="4247.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV Type 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="234"/>
                    <count group_id="O2" value="236"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="884.3" lower_limit="766.4" upper_limit="1020.4"/>
                    <measurement group_id="O2" value="790.9" lower_limit="683.0" upper_limit="915.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>HPV Type 6</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority required that the lower bound of the two-sided confidence interval (CI) of the GMT ratio was &gt;0.50</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <param_type>GMT Ratio</param_type>
            <param_value>1.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.04</ci_lower_limit>
            <ci_upper_limit>1.45</ci_upper_limit>
            <estimate_desc>GMT ratio = GMT (V503) / GMT (Gardasil)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>HPV Type 11</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority required that the lower bound of the two-sided confidence interval (CI) of the GMT ratio was &gt;0.50</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <param_type>GMT Ratio</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
            <estimate_desc>GMT ratio = GMT (V503) / GMT (Gardasil)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>HPV Type 16</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority required that the lower bound of the two-sided confidence interval (CI) of the GMT ratio was &gt;0.50</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <param_type>GMT Ratio</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
            <estimate_desc>GMT ratio = GMT (V503) / GMT (Gardasil)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>HPV Type 18</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority required that the lower bound of the two-sided confidence interval (CI) of the GMT ratio was &gt;0.50</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <param_type>GMT Ratio</param_type>
            <param_value>1.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>1.37</ci_upper_limit>
            <estimate_desc>GMT ratio = GMT (V503) / GMT (Gardasil)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMTs to HPV Types 31/33/45/52/58</title>
        <description>Serum antibodies to HPV types 31, 33, 45, 52, and 58 were measured with a Competitive Luminex Immunoassay. Titers are reported in milli Merck Units/mL.</description>
        <time_frame>4 weeks postdose 3 (Month 7)</time_frame>
        <population>All randomized participants. The number contributing to each data point is participants who received all 3 vaccinations within acceptable day ranges, had Month 7 serology for the HPV type within acceptable day ranges, were seronegative at Day 1, and had no protocol violations that interfered with evaluation of immune response</population>
        <group_list>
          <group group_id="O1">
            <title>V503</title>
            <description>9-valent HPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6</description>
          </group>
          <group group_id="O2">
            <title>GARDASIL</title>
            <description>Quadrivalent HPV [Types 6, 11, 16, and 18] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6</description>
          </group>
        </group_list>
        <measure>
          <title>GMTs to HPV Types 31/33/45/52/58</title>
          <description>Serum antibodies to HPV types 31, 33, 45, 52, and 58 were measured with a Competitive Luminex Immunoassay. Titers are reported in milli Merck Units/mL.</description>
          <population>All randomized participants. The number contributing to each data point is participants who received all 3 vaccinations within acceptable day ranges, had Month 7 serology for the HPV type within acceptable day ranges, were seronegative at Day 1, and had no protocol violations that interfered with evaluation of immune response</population>
          <units>milli Merck U/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="251"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV Type 31</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="234"/>
                    <count group_id="O2" value="237"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="794.4" lower_limit="694.2" upper_limit="909.2"/>
                    <measurement group_id="O2" value="14.8" lower_limit="12.5" upper_limit="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV Type 33</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="236"/>
                    <count group_id="O2" value="236"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="460.5" lower_limit="410.6" upper_limit="516.4"/>
                    <measurement group_id="O2" value="3.4" lower_limit="3.1" upper_limit="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV Type 45</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="232"/>
                    <count group_id="O2" value="236"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="262.9" lower_limit="226.2" upper_limit="305.5"/>
                    <measurement group_id="O2" value="2.5" lower_limit="2.3" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV Type 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="235"/>
                    <count group_id="O2" value="236"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="430.7" lower_limit="377.8" upper_limit="491.0"/>
                    <measurement group_id="O2" value="1.9" lower_limit="1.8" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV Type 58</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="232"/>
                    <count group_id="O2" value="233"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="691.0" lower_limit="614.9" upper_limit="776.5"/>
                    <measurement group_id="O2" value="5.7" lower_limit="5.0" upper_limit="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Are Seropositive for HPV Types 6/11/16/18/31/33/45/52/58</title>
        <description>Serum antibodies to HPV types were measured with a Competitive Luminex Immunoassay. The serostatus cutoffs (milli Merck U/mL) for HPV types were as follows: HPV Type 6: ≥30; HPV Type 11: ≥16; HPV Type 16: ≥20; HPV Type 18: ≥24; HPV Type 31: ≥10; HPV Type 33: ≥8; HPV Type 45: ≥8; HPV Type 52: ≥8; HPV Type 58: ≥8.</description>
        <time_frame>4 weeks postdose 3 (Month 7)</time_frame>
        <population>All randomized participants. The number contributing to each data point is participants who received all 3 vaccinations within acceptable day ranges, had Month 7 serology for the HPV type within acceptable day ranges, were seronegative at Day 1, and had no protocol violations that interfered with evaluation of immune response.</population>
        <group_list>
          <group group_id="O1">
            <title>V503</title>
            <description>9-valent HPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6</description>
          </group>
          <group group_id="O2">
            <title>GARDASIL</title>
            <description>Quadrivalent HPV [Types 6, 11, 16, and 18] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Are Seropositive for HPV Types 6/11/16/18/31/33/45/52/58</title>
          <description>Serum antibodies to HPV types were measured with a Competitive Luminex Immunoassay. The serostatus cutoffs (milli Merck U/mL) for HPV types were as follows: HPV Type 6: ≥30; HPV Type 11: ≥16; HPV Type 16: ≥20; HPV Type 18: ≥24; HPV Type 31: ≥10; HPV Type 33: ≥8; HPV Type 45: ≥8; HPV Type 52: ≥8; HPV Type 58: ≥8.</description>
          <population>All randomized participants. The number contributing to each data point is participants who received all 3 vaccinations within acceptable day ranges, had Month 7 serology for the HPV type within acceptable day ranges, were seronegative at Day 1, and had no protocol violations that interfered with evaluation of immune response.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="251"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV Type 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="228"/>
                    <count group_id="O2" value="226"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.2" lower_limit="95.6" upper_limit="99.5"/>
                    <measurement group_id="O2" value="98.7" lower_limit="96.2" upper_limit="99.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV Type 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="228"/>
                    <count group_id="O2" value="226"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98.4" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="98.4" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV Type 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="234"/>
                    <count group_id="O2" value="237"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98.4" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="98.5" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV Type 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="234"/>
                    <count group_id="O2" value="236"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.6" lower_limit="97.6" upper_limit="100"/>
                    <measurement group_id="O2" value="99.6" lower_limit="97.7" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV Type 31</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="234"/>
                    <count group_id="O2" value="237"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98.4" upper_limit="100"/>
                    <measurement group_id="O2" value="61.6" lower_limit="55.1" upper_limit="67.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV Type 33</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="236"/>
                    <count group_id="O2" value="236"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98.4" upper_limit="100"/>
                    <measurement group_id="O2" value="16.9" lower_limit="12.4" upper_limit="22.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV Type 45</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="232"/>
                    <count group_id="O2" value="236"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98.4" upper_limit="100"/>
                    <measurement group_id="O2" value="9.3" lower_limit="5.9" upper_limit="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV Type 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="235"/>
                    <count group_id="O2" value="236"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98.4" upper_limit="100"/>
                    <measurement group_id="O2" value="2.5" lower_limit="0.9" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV Type 58</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="232"/>
                    <count group_id="O2" value="233"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98.4" upper_limit="100"/>
                    <measurement group_id="O2" value="36.1" lower_limit="29.9" upper_limit="42.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With One or More Adverse Events</title>
        <description>The percentage of participants with one or more adverse events was assessed.</description>
        <time_frame>Up to 15 days after any vaccination</time_frame>
        <population>All participants who received at least one study vaccination and had safety follow-up data</population>
        <group_list>
          <group group_id="O1">
            <title>V503</title>
            <description>9-valent HPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6</description>
          </group>
          <group group_id="O2">
            <title>GARDASIL</title>
            <description>Quadrivalent HPV [Types 6, 11, 16, and 18] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With One or More Adverse Events</title>
          <description>The percentage of participants with one or more adverse events was assessed.</description>
          <population>All participants who received at least one study vaccination and had safety follow-up data</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="248"/>
                <count group_id="O2" value="248"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.3" lower_limit="76.9" upper_limit="86.8"/>
                    <measurement group_id="O2" value="81.9" lower_limit="76.5" upper_limit="86.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Study Discontinuation Due to an Adverse Event</title>
        <description>The percentage of participants discontinued from the study due to an adverse event was assessed.</description>
        <time_frame>Up to Month 7</time_frame>
        <population>All participants who received at least one study vaccination and had safety follow-up data</population>
        <group_list>
          <group group_id="O1">
            <title>V503</title>
            <description>9-valent HPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6</description>
          </group>
          <group group_id="O2">
            <title>GARDASIL</title>
            <description>Quadrivalent HPV [Types 6, 11, 16, and 18] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Study Discontinuation Due to an Adverse Event</title>
          <description>The percentage of participants discontinued from the study due to an adverse event was assessed.</description>
          <population>All participants who received at least one study vaccination and had safety follow-up data</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="248"/>
                <count group_id="O2" value="248"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="1.5"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With One or More Injection-site Adverse Reactions</title>
        <description>The percentage of participants with one or more injection-site adverse reactions (solicited or unsolicited) was assessed.</description>
        <time_frame>Up to 5 days after any vaccination</time_frame>
        <population>All participants who received at least one study vaccination and had safety follow-up data</population>
        <group_list>
          <group group_id="O1">
            <title>V503</title>
            <description>9-valent HPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6</description>
          </group>
          <group group_id="O2">
            <title>GARDASIL</title>
            <description>Quadrivalent HPV [Types 6, 11, 16, and 18] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With One or More Injection-site Adverse Reactions</title>
          <description>The percentage of participants with one or more injection-site adverse reactions (solicited or unsolicited) was assessed.</description>
          <population>All participants who received at least one study vaccination and had safety follow-up data</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="248"/>
                <count group_id="O2" value="248"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.0" lower_limit="73.4" upper_limit="83.9"/>
                    <measurement group_id="O2" value="72.2" lower_limit="66.2" upper_limit="77.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Maximum Temperature ≥37.8 °C</title>
        <description>The percentage of participants with a maximum temperature ≥37.8 °C was assessed.</description>
        <time_frame>Up to 5 days after any vaccination</time_frame>
        <population>All participants who received at least one study vaccination and had safety follow-up data</population>
        <group_list>
          <group group_id="O1">
            <title>V503</title>
            <description>9-valent HPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6</description>
          </group>
          <group group_id="O2">
            <title>GARDASIL</title>
            <description>Quadrivalent HPV [Types 6, 11, 16, and 18] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Maximum Temperature ≥37.8 °C</title>
          <description>The percentage of participants with a maximum temperature ≥37.8 °C was assessed.</description>
          <population>All participants who received at least one study vaccination and had safety follow-up data</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="248"/>
                <count group_id="O2" value="248"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8"/>
                    <measurement group_id="O2" value="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With One or More Systemic Adverse Events</title>
        <description>The percentage of participants with one or more systemic adverse events was assessed.</description>
        <time_frame>Up to 15 days after any vaccination</time_frame>
        <population>All participants who received at least one study vaccination and had safety follow-up data</population>
        <group_list>
          <group group_id="O1">
            <title>V503</title>
            <description>9-valent HPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6</description>
          </group>
          <group group_id="O2">
            <title>GARDASIL</title>
            <description>Quadrivalent HPV [Types 6, 11, 16, and 18] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With One or More Systemic Adverse Events</title>
          <description>The percentage of participants with one or more systemic adverse events was assessed.</description>
          <population>All participants who received at least one study vaccination and had safety follow-up data</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="248"/>
                <count group_id="O2" value="248"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.7" lower_limit="34.6" upper_limit="47.1"/>
                    <measurement group_id="O2" value="40.3" lower_limit="34.2" upper_limit="46.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With One or More Serious Adverse Events</title>
        <description>The percentage of participants with one or more serious adverse events was assessed.</description>
        <time_frame>Up to 15 days after any vaccination</time_frame>
        <population>All participants who received at least one study vaccination and had safety follow-up data</population>
        <group_list>
          <group group_id="O1">
            <title>V503</title>
            <description>9-valent HPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6</description>
          </group>
          <group group_id="O2">
            <title>GARDASIL</title>
            <description>Quadrivalent HPV [Types 6, 11, 16, and 18] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With One or More Serious Adverse Events</title>
          <description>The percentage of participants with one or more serious adverse events was assessed.</description>
          <population>All participants who received at least one study vaccination and had safety follow-up data</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="248"/>
                <count group_id="O2" value="248"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="1.5"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All adverse events: up to 15 days after each vaccination; serious adverse events: up to Month 7</time_frame>
      <group_list>
        <group group_id="E1">
          <title>V503</title>
          <description>9-valent HPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6</description>
        </group>
        <group group_id="E2">
          <title>GARDASIL</title>
          <description>Quadrivalent HPV [Types 6, 11, 16, and 18] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="248"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="248"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="248"/>
              </event>
              <event>
                <sub_title>Ligament injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="248"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="248"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version 17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="196" subjects_at_risk="248"/>
                <counts group_id="E2" subjects_affected="189" subjects_at_risk="248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection-site erythema</sub_title>
                <counts group_id="E1" events="62" subjects_affected="38" subjects_at_risk="248"/>
                <counts group_id="E2" events="64" subjects_affected="43" subjects_at_risk="248"/>
              </event>
              <event>
                <sub_title>Injection-site pain</sub_title>
                <counts group_id="E1" events="443" subjects_affected="193" subjects_at_risk="248"/>
                <counts group_id="E2" events="350" subjects_affected="174" subjects_at_risk="248"/>
              </event>
              <event>
                <sub_title>Injection-site swelling</sub_title>
                <counts group_id="E1" events="47" subjects_affected="36" subjects_at_risk="248"/>
                <counts group_id="E2" events="35" subjects_affected="23" subjects_at_risk="248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="248"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="43" subjects_affected="29" subjects_at_risk="248"/>
                <counts group_id="E2" events="51" subjects_affected="37" subjects_at_risk="248"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

